Opioid Induced Constipation Drugs Market – Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016-2022, the opioid induced constipation drugs market was valued at USD 2111.05 Mn in 2017, and is expected to reach USD 2887.91 Mn by 2025, expanding at a CAGR of 4.6% from 2017 to 2025.
Browse Full Report Here: http://www.acutemarketreports.com/report/opioid-induced-constipation-drugs-market
Alarming growth in opioid prescription for non-cancer pain has been a phenomenal event in the previous decade. As per the recent estimates, more than 40% of opioid consumers experience constipation and GI symptoms as side effects of opioid drugs. Rising pool of opioid users will lead to the growth in opioid induced constipation (OIC) prevalence thus contributing to OIC drugs market growth. The global opioid induced constipation drugs market was valued at USD 2111.05 Mn in 2017, and is expected to reach USD 2887.91 Mn by 2025, expanding at a CAGR of 4.6% from 2017 to 2025.
Methylnaltrexone bromide, lubiprostone and naloxegol are the three drugs currently indicated for OIC treatment. Among these, methylnaltrexone bromide holds the largest market size and is expected to progress with a CAGR of 2.9% during the forecast period. Relistor from Salix Pharmaceuticals is indicated for treatment of OIC in patients with advanced illness receiving palliative care, particularly when standard laxative therapy proves insufficient. Lubiprostone under the brandname Amitiza is indicated for treating OIC, where it major indication is for chronic idiopathic constipation (CIC). Lubiprostone is expected that the segment will take over the market share of methylnaltrexone bromide. Additionally, naloxegol is expected to grow at highest CAGR over the forecast period. The drug is under testing for various patient types such as pregnant women and patients less than 17 years of age. Thus, future approvals are expected to lead the market.
Browse the complete report at: http://www.acutemarketreports.com/report/opioid-induced-constipation-drugs-market
North America is the dominant regional OIC drugs market through the forecast period. Early bird approval of OIC drugs by the USFDA and high consumption of opioids in the US are the prime growth factors for the OIC drugs market in North America. On the other hand, Germany, UK, and Spain are the major countries setting the market dynamics in Europe. Overall, the developed countries across the world, predominantly North America and Europe are the key consumers of OIC drugs.
Table of Content:
Download Free Request Sample: http://www.acutemarketreports.com/request-free-sample/103779
Chapter 1 Preface
1.1 Report Scope and Description
1.2 Research Methodology
Chapter 2 Executive Summary
2.1 Opioid Induced Constipation (OIC) Drugs Market Industry Snapshot
Chapter 3 Global OIC Drugs Market Analysis
3.1 OIC Drugs Market Overview
3.2 Market Inclination Insights
3.3 Market Dynamics
18.104.22.168 Increasing Use of Opioid
22.214.171.124 Elderly Population
126.96.36.199 Rising Opioids Prescription in North America and Europe
188.8.131.52 Large Range of Effective OIC Drugs Available
184.108.40.206 Research on Pain and Next Generation Analgesics
220.127.116.11 Adverse Effects of OIC Drugs
18.104.22.168 Unawareness and hesitation among patients
22.214.171.124 Large number of considerations while using opioids
126.96.36.199 Emerging APAC Market
188.8.131.52 Rising Use of Opioids
3.4 Attractive Investment Proposition, 2017
3.5 Market Positioning of Key OIC Drugs Manufacturers
Chapter 7 Company Profiles
7.1.2 Astrazeneca Product Portfolio
7.1.3 SCOT Analysis
7.2 Shionogo & Co Ltd
7.2.2 Shionogi product portfolio
7.2.3 Scot Analysis
7.3 Salix Pharmaceuticals Ltd
7.3.2 Salix Pharmaceuticals product portfolio
7.3.3 SCOT Analysis
7.4 Synergy Pharmaceuticals Inc
7.4.2 Synergy Pharmaceuticals Product Portfolio
7.4.3 SCOT Analysis
7.5 Cubist Pharmaceuticals (Adolor Corporation) – A Subsidary Of Merck
7.5.2 Cubist Pharmaceuticals Product Portfolio
7.5.3 SCOT Analysis
7.6 Sucampo Pharmaceuticals
7.6.2 Sucampo Pharmaceuticals Product Portfolio
7.6.3 SCOT Analysis
7.7 Ironwood Pharmaceuticals, Inc.
7.7.2 Ironwood Pharmaceuticals Inc. Products Portfolio
7.7.3 SCOT Analysis
7.8 Daiichi Sankyo Co. Ltd.
7.8.2 Daiichi Sankyo Product Portfolio
7.8.3 SCOT Analysis
7.9.2 Pfizer Product Portfolio
7.9.3 SCOT Analysis
7.10 Progenics Pharmaceuticals Inc
7.10.2 Progenics Pharmaceuticals Product Portfolio
7.10.3 SCOT Analysis
About – Acute Market Reports:
Acute Market Reports is the most sufficient collection of market intelligence services online. It is your only source that can fulfill all your market research requirements. We provide online reports from over 100 best publishers and upgrade our collection regularly to offer you direct online access to the world’s most comprehensive and recent database with expert perceptions on worldwide industries, products, establishments and trends.
Our team consists of highly motivated market research professionals and they are accountable for creating the groundbreaking technology that we utilize in our search engine operations to easily recognize the most current market research reports online.